Cure8 news brief
New Phase 3 and long‑term analyses presented at ACG 2026 report that risankizumab and upadacitinib showed disease control in patients with moderate‑to‑severe IBD, including difficult‑to‑treat Crohn’s disease. These findings may be relevant to patients and clinicians considering advanced therapies.
People with moderate-to-severe Crohn’s disease (including fistulizing or stricturing disease), patients with ulcerative colitis, clinicians treating IBD, and researchers in IBD drug development.
This AbbVie press release summarizes Phase 3 AFFIRM and multiple open‑label extension and real-world analyses of risankizumab (SKYRIZI) and upadacitinib (RINVOQ) presented at ACG 2026.
It highlights higher rates of clinical remission and endoscopic response with subcutaneous risankizumab versus placebo in the AFFIRM trial, long‑term endoscopic outcomes from FORTIFY/SEQUENCE/COMMAND open‑label extension analyses, and real‑world outcomes for upadacitinib in difficult‑to‑treat Crohn’s disease including fistulizing and stricturing disease.
The release is promotional and summarizes conference presentations and posters rather than presenting full peer‑reviewed manuscripts; specific methods, patient counts, statistical details, and safety data are not fully reported here.
For treatment decisions, consult your gastroenterology team and review the full study reports or peer‑reviewed publications when available.
People with Crohn’s disease (including fistulizing or stricturing disease), patients with moderate-to-severe ulcerative colitis, clinicians treating IBD, researchers, and patients already on or considering biologic/JAK therapy. This is an AbbVie corporate press release about abstracts presented at a medical meeting.
Conference abstracts and company summaries may not include complete data or independent peer review; full study publications and regulatory guidance should be consulted for clinical decision making.
Findings are reported in a company press release summarizing conference presentations and abstracts. Detailed methods, full efficacy and safety data, and peer‑reviewed publication status are not provided in this release; interpret results cautiously until full study reports are available.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
New trial and real-world data about Skyrizi and Rinvoq could affect treatment options and conversations about long-term outcomes for people with Crohn’s disease or ulcerative colitis. Investors’ coverage can increase...
New long-term and real-world data on SKYRIZI and RINVOQ were presented at DDW, which may influence how clinicians, payers, and patients view these options for Crohn's disease and ulcerative colitis.
Growth and new approvals for Skyrizi and Rinvoq may increase treatment options and influence which drugs gastroenterologists prescribe for Crohn’s disease and ulcerative colitis. Changes in approvals, dosing options, and...
